Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond.

Area of Science:

• Pharmacology
• Virology
• Medicinal Chemistry

Background:

• Nucleotide reverse transcriptase inhibitors (NtRTIs) represent a significant class of antiretroviral agents.
• Tenofovir disoproxil fumarate is the sole approved NtRTI for HIV treatment.
• Ongoing research explores novel nucleotide-based therapeutics and prodrug strategies.

Purpose of the Study:

• To review the class of nucleotide HIV reverse transcriptase inhibitors.
• To summarize recent findings on tenofovir and its prodrug, tenofovir disoproxil fumarate.
• To discuss novel strategies in the design of anti-HIV nucleotides and prodrugs.

Main Methods:

• Review of existing literature on nucleotide HIV reverse transcriptase inhibitors.
• Analysis of clinical efficacy and safety data for tenofovir disoproxil fumarate.
• Exploration of preclinical and clinical studies on novel nucleotide analogs and prodrugs.

Main Results:

• Tenofovir disoproxil fumarate demonstrates potent and durable efficacy in combination antiretroviral therapy for HIV.
• Prophylactic effects of tenofovir and tenofovir disoproxil fumarate are under investigation in animal models and clinical studies.
• Efficacy against hepatitis B virus is established, with ongoing phase III trials.
• GS-7340, an alternative tenofovir prodrug, highlights the potential of phosphonoamidates for nucleotide delivery.

Conclusions:

• Tenofovir disoproxil fumarate validates nucleotides as effective antiretroviral therapeutics with a favorable safety profile.
• Novel nucleotide reverse transcriptase inhibitors, including GS-9148, PMDTA, and PMEO, are emerging from drug discovery.
• Continued development of nucleotide-based therapies holds promise for improved HIV management.